Human Papillomavirus (HPV)



Zinc Sulfate for Human Papillomavirus (HPV)


Condition:   Human Papilloma Virus
Interventions:   Dietary Supplement: Zinc Sulfate;   Other: Placebo (Gelatin Tablet)
Sponsor:   Spectrum Health Hospitals
Recruiting


HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV


Condition:   Human Papilloma Virus
Intervention:   Biological: HPV-CTLs
Sponsor:   Shenzhen Geno-Immune Medical Institute
Recruiting


Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)


Conditions:   Human Papillomavirus;   Human Papillomavirus Infection
Intervention:  
Sponsors:   The Alfred;   Merck Sharp & Dohme Corp.
Recruiting


txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men


Condition:   Human Papillomavirus
Interventions:   Behavioral: txt2protect;   Behavioral: Sexual Health Knowledge Control
Sponsors:   Northwestern University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Recruiting


Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine


Condition:   Human Papillomavirus
Intervention:   Biological: Human Papillomavirus 9-valent Vaccine, Recombinant
Sponsors:   University of British Columbia;   Merck Canada Inc
Recruiting


Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination


Conditions:   Papillomavirus Infections;   Health Behavior;   Attitude of Health Personnel;   Human Papilloma Virus, Male
Intervention:   Other: Survey
Sponsor:   Louisiana State University Health Sciences Center Shreveport
Active, not recruiting


Observational Follow up of Prior HPV Vaccinees


Condition:   Human Papillomavirus Virus
Intervention:   Other: venepuncture
Sponsor:   Public Health England
Completed


Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort


Condition:   Human Papillomavirus-Related Cervical Carcinoma
Intervention:   Other: Agreement between oral and cervical HPV infection
Sponsor:   Institut de Cancérologie de Lorraine
Recruiting


Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females


Condition:   Human Papillomavirus
Interventions:   Biological: HPV vaccine;   Biological: Placebo
Sponsor:   Shanghai Zerun Biotechnology Co.,Ltd
Active, not recruiting


Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females


Conditions:   Human Papillomavirus;   Cervical Intraepithelial Neoplasia;   Persistent Infection
Intervention:   Biological: HPV-16/18 vaccine
Sponsors:   Shanghai Zerun Biotechnology Co.,Ltd;   Guangxi Center for Disease Control and Prevention
Recruiting


Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)


Condition:   Human Papilloma Virus Infection
Interventions:   Other: First-void urine collection;   Other: Blood draw
Sponsors:   Universiteit Antwerpen;   Research Foundation Flanders
Completed


Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy


Condition:   Human Papillomavirus
Interventions:   Procedure: Tonsil Biopsy;   Procedure: Smear
Sponsor:   University Hospital, Toulouse
Completed


Lubricant Investigation in Men to Inhibit Transmission of HPV Infection


Condition:   Human Papillomavirus Infection
Interventions:   Other: Carrageenan-based gel;   Other: Control gel
Sponsors:   McGill University;   Université de Montréal
Recruiting


Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies


Conditions:   Human Papillomavirus (HPV)-Related Malignancies;   Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Intervention:   Drug: Ribavirin
Sponsor:   Memorial Sloan Kettering Cancer Center
Active, not recruiting


Prevention of HPV in the School Health Service


Conditions:   Human Papillomavirus;   Cervix Cancer
Intervention:   Behavioral: Education about HPV by school nurse
Sponsors:   Uppsala University;   Swedish Cancer Society;   Uppsala-Örebro Regional Research Council
Completed


Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents


Condition:   Human Papillomavirus
Interventions:   Behavioral: Conventional text message reminder;   Behavioral: Enhanced text message reminders
Sponsors:   Columbia University;   Agency for Healthcare Research and Quality (AHRQ)
Active, not recruiting


A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)


Condition:   Human Papillomavirus Infection
Intervention:   Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors


Conditions:   Cancer Survivor;   Prevention of Human Papillomavirus Infection
Interventions:   Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58);   Other: laboratory biomarker analysis;   Other: survey administration;   Other: medical chart review
Sponsors:   University of Alabama at Birmingham;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
Recruiting


Study of Gardasil in Mid-Adult Males (MAM)


Condition:   Human Papillomavirus
Intervention:   Biological: Gardasil
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
Active, not recruiting


Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time


Conditions:   Oropharyngeal Cancer;   Human Papillomavirus
Intervention:  
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Icahn School of Medicine at Mount Sinai;   Oregon Health and Science University;   Dana-Farber Cancer Institute;   Johns Hopkins University
Completed


Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)


Condition:   Human Papillomavirus
Interventions:   Biological: V503;   Biological: GARDASIL
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Prevalence of Human Papillomavirus in Men Living in the Northern Plains


Condition:   Human Papillomavirus Infection
Intervention:  
Sponsor:   Sanford Health
Completed


Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)


Condition:   Human Papillomavirus Infection
Intervention:  
Sponsors:   Merck Sharp & Dohme Corp.;   Kaiser Permanente
Completed


A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)


Condition:   Human Papillomavirus Infection
Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (Concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls


Conditions:   Cervical Cancer;   Human Papillomavirus;   Anal Cancer;   Oral Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Refine Your Search Advanced Search